Healthcare
Live Price
Offline$0.06
+0.00% today
1Y Change
-50.00%
Window
Jul 1, 2025 → Jun 10, 2026
Coverage: 19 bars · Jul 1, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ligand Pharmaceuticals, Inc. (LGNZZ) is a Healthcare stock with a market cap of $4.68B and listed on OTC. The stock last traded around $0.06 and down 50.0% across the available one-year price window (Jul 1, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +60.4%, EPS growth of +1188.0%, a dividend yield of 0.0%. What stands out right now is revenue +60.4%, EPS +1188.0%, free cash flow -48.6% with operating margin 17.6% and ROIC 2.4%. Valuation already assumes a fairly strong business story at P/E 37.2 and price/sales 17.5. Stock Foundry combines LGNZZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
LGNZZ is 67.45 pts behind over the shared 1Y window.
LGNZZ had 40.87 pts deeper max drawdown than SPY.
LGNZZ beat SPY in 0 of 2 calendar years shown and trailed in 2.
LGNZZ
-50.00%
Normalized return
SPY
+17.45%
S&P 500
Excess Return
-67.45 pts
Relative to SPY
LGNZZ Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for LGNZZ and SPY.
| Year | LGNZZ | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -14.29% | +6.71% | -20.99 pts | SPY |
| 2025 | -37.50% | +11.19% | -48.69 pts | SPY |
Unable to load analyst forecasts.
Timed out loading forecasts for LGNZZ
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.